Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ, Michael DOUBEK and Michal ŠMÍDA. Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. In XVIII. International Workshop on CLL, Edinburgh, Skotsko. 2020. ISSN 1042-8194.

Basic information

• Original name: Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells
• Authors: KOZLOVÁ, Veronika (203 Czech Republic, belonging to the institution), Aneta LEDEREROVÁ (203 Czech Republic, belonging to the institution), Veronika MANČÍKOVÁ (703 Slovakia, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, belonging to the institution).
• Edition: XVIII. International Workshop on CLL, Edinburgh, Skotsko, 2020.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30204 Oncology
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 3.280
• RIV identification code: RIV/00216224:14740/20:00115243
• Organization unit: Central European Institute of Technology
• ISSN: 1042-8194
• UT WoS: 000534385400182
• Keywords in English: CD20; CLL cells
• Tags: rivok
• Tags: International impact

Abstract

In spite of recent advancements in the therapy of B-cell malignancies, CD20-targeted monoclonal antibodies (mAbs) still remain the key part of therapy in clinical practice. Furthermore, the combination of CD20 mAbs with targeted agents is being tested in clinical trials. Therefore, the knowledge of CD20 regulation remains a critical issue to address. Despite using CD20 as the prime target of therapy for decades now, the information about its function and molecular mechanisms remains to be scarce. Since low expression of CD20 on the surface of malignant B cells represents an important basis for CD20 antibody therapy failure, the idea of modulating CD20 levels seems an appealing strategy to enhance the success rate of CD20 immunotherapy

Links

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

• MUNI/A/1105/2018, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI (Acronym: VýDiTeHeMA VI)

Investor: Masaryk University, Category A

• NV15-33561A, research and development project: Name: Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie